LEI: 549300Q7EXQQH6KF7Z84
15 May 2024
RTW Biotech Opportunities Ltd
Additional Investment in Lycia Therapeutics
| • | Lycia Therapeutics completes $106.6 million Series C financing |
| • | Lycia is a leader in extracellular protein degradation |
| • | Proceeds to progress lead programmes into the clinic for autoimmune and inflammatory diseases |
| |
|
RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by portfolio company, Lycia Therapeutics ("Lycia"), of its completion of a $106.6 million Series C financing round.
The Company, alongside other investment vehicles managed by RTW Investments, LP (the "Investment Manager"), participated in the financing round with other life science investment firms. The Company first invested in Lycia's Series B financing round in January 2021. Lycia intends to use the net proceeds to progress its LYTAC degraders into clinical trials for patients with autoimmune and inflammatory diseases.
Lycia is a biotechnology company using its proprietary lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory diseases.
Josh Kennedy-Smith, PhD, Partner and Research Analyst at the Investment Manager, said, "Lycia is working at the cutting edge of extracellular protein degradation, and we are thrilled to continue our support of the company as they progress the development of multiple LYTAC degraders towards proof of concept in patients with autoimmune disease."
The full text of these announcements can be accessed on Lycia's website: https://lyciatx.com/.
For Further Information
| RTW Investments, LP | +44 20 7959 6361 |
| Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations | |
|
Buchanan (PR & Communications Adviser) |
+44 20 7466 5107 |
| Charles Ryland |
|
| Henry Wilson |
|
| George Beale |
|
|
|
|
| Deutsche Numis (Joint Corporate Broker) | +44 20 7260 1000 |
| Freddie Barnfield |
|
| Nathan Brown |
|
| Euan Brown |
|
| |
|
| BofA Securities (Joint Corporate Broker) | +44 20 7628 1000 |
| Edward Peel |
|
| Alex Penney |
|
|
Cadarn Capital (Distribution & IR Partner) |
+44 73 6888 3211 |
| David Harris |
|
|
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director
|
+44 14 8181 0100 |
| Morgan Stanley Fund Services USA LLC | +1 914 225 8885 |
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.
The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.
***********
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
